CRISPR Therapeutics AG — Director's Dealing 2017

Feb 10, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2016-10-24

Reporting Person: Lundberg Sven Ante (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-10-24	Common Shares	C	55217	$0.00	Acquired	505217	Direct
2016-10-24	Common Shares	P	400	$14.00	Acquired	505617	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-10-24	Series B Preferred Shares	$0.00	C	55217	Disposed		Common Shares (55217)	Direct

Footnotes

F1: These securities were convertible at any time on a one-for-one basis into shares of the Issuer's Common Stock at the holder's election and automatically upon the closing of the Issuer's initial public offering. These securities do not have an expiration date.